SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma

Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Rueda Domínguez, A. [verfasserIn] Alfaro Lizaso, J. [verfasserIn] de la Cruz Merino, L. [verfasserIn] Gumá i Padró, J. [verfasserIn] Quero Blanco, C. [verfasserIn] Gómez Codina, J. [verfasserIn] Llanos Muñoz, M. [verfasserIn] Martinez Banaclocha, N. [verfasserIn] Rodriguez Abreu, D. [verfasserIn] Provencio Pulla, M. [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2015

Schlagwörter:	Oncohematology malignancies Hodgkin lymphoma Hodgkin lymphoma therapy

Übergeordnetes Werk:	Enthalten in: Revista de oncología - Barcelona : Doyma, 2000, 17(2015), 12 vom: 26. Okt., Seite 1005-1013
Übergeordnetes Werk:	volume:17 ; year:2015 ; number:12 ; day:26 ; month:10 ; pages:1005-1013

Links:	Volltext

DOI / URN:	10.1007/s12094-015-1429-1

Katalog-ID:	SPR024262714

Internformat


LEADER	01000caa a22002652 4500
001	SPR024262714
003	DE-627
005	20230519164623.0
007	cr uuu---uuuuu
008	201006s2015 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s12094-015-1429-1 \|2 doi
035			\|a (DE-627)SPR024262714
035			\|a (SPR)s12094-015-1429-1-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q ASE
100	1		\|a Rueda Domínguez, A. \|e verfasserin \|4 aut
245	1	0	\|a SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma
264		1	\|c 2015
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.
650		4	\|a Oncohematology malignancies \|7 (dpeaa)DE-He213
650		4	\|a Hodgkin lymphoma \|7 (dpeaa)DE-He213
650		4	\|a Hodgkin lymphoma therapy \|7 (dpeaa)DE-He213
700	1		\|a Alfaro Lizaso, J. \|e verfasserin \|4 aut
700	1		\|a de la Cruz Merino, L. \|e verfasserin \|4 aut
700	1		\|a Gumá i Padró, J. \|e verfasserin \|4 aut
700	1		\|a Quero Blanco, C. \|e verfasserin \|4 aut
700	1		\|a Gómez Codina, J. \|e verfasserin \|4 aut
700	1		\|a Llanos Muñoz, M. \|e verfasserin \|4 aut
700	1		\|a Martinez Banaclocha, N. \|e verfasserin \|4 aut
700	1		\|a Rodriguez Abreu, D. \|e verfasserin \|4 aut
700	1		\|a Provencio Pulla, M. \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Revista de oncología \|d Barcelona : Doyma, 2000 \|g 17(2015), 12 vom: 26. Okt., Seite 1005-1013 \|w (DE-627)385985452 \|w (DE-600)2143451-7 \|x 1578-195X \|7 nnns
773	1	8	\|g volume:17 \|g year:2015 \|g number:12 \|g day:26 \|g month:10 \|g pages:1005-1013
856	4	0	\|u https://dx.doi.org/10.1007/s12094-015-1429-1 \|z kostenfrei \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_120
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_224
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
951			\|a AR
952			\|d 17 \|j 2015 \|e 12 \|b 26 \|c 10 \|h 1005-1013

Indexfelder

author_variant	d a r da dar l j a lj lja l c m l d lcml lcmld i p j g ipj ipjg b c q bc bcq c j g cj cjg m m l mm mml b n m bn bnm a d r ad adr p m p pm pmp
matchkey_str	article:1578195X:2015----::emlncludlnsoteramno
hierarchy_sort_str	2015
publishDate	2015
allfields	10.1007/s12094-015-1429-1 doi (DE-627)SPR024262714 (SPR)s12094-015-1429-1-e DE-627 ger DE-627 rakwb eng 610 ASE Rueda Domínguez, A. verfasserin aut SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. Oncohematology malignancies (dpeaa)DE-He213 Hodgkin lymphoma (dpeaa)DE-He213 Hodgkin lymphoma therapy (dpeaa)DE-He213 Alfaro Lizaso, J. verfasserin aut de la Cruz Merino, L. verfasserin aut Gumá i Padró, J. verfasserin aut Quero Blanco, C. verfasserin aut Gómez Codina, J. verfasserin aut Llanos Muñoz, M. verfasserin aut Martinez Banaclocha, N. verfasserin aut Rodriguez Abreu, D. verfasserin aut Provencio Pulla, M. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 17(2015), 12 vom: 26. Okt., Seite 1005-1013 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:17 year:2015 number:12 day:26 month:10 pages:1005-1013 https://dx.doi.org/10.1007/s12094-015-1429-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 17 2015 12 26 10 1005-1013
spelling	10.1007/s12094-015-1429-1 doi (DE-627)SPR024262714 (SPR)s12094-015-1429-1-e DE-627 ger DE-627 rakwb eng 610 ASE Rueda Domínguez, A. verfasserin aut SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. Oncohematology malignancies (dpeaa)DE-He213 Hodgkin lymphoma (dpeaa)DE-He213 Hodgkin lymphoma therapy (dpeaa)DE-He213 Alfaro Lizaso, J. verfasserin aut de la Cruz Merino, L. verfasserin aut Gumá i Padró, J. verfasserin aut Quero Blanco, C. verfasserin aut Gómez Codina, J. verfasserin aut Llanos Muñoz, M. verfasserin aut Martinez Banaclocha, N. verfasserin aut Rodriguez Abreu, D. verfasserin aut Provencio Pulla, M. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 17(2015), 12 vom: 26. Okt., Seite 1005-1013 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:17 year:2015 number:12 day:26 month:10 pages:1005-1013 https://dx.doi.org/10.1007/s12094-015-1429-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 17 2015 12 26 10 1005-1013
allfields_unstemmed	10.1007/s12094-015-1429-1 doi (DE-627)SPR024262714 (SPR)s12094-015-1429-1-e DE-627 ger DE-627 rakwb eng 610 ASE Rueda Domínguez, A. verfasserin aut SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. Oncohematology malignancies (dpeaa)DE-He213 Hodgkin lymphoma (dpeaa)DE-He213 Hodgkin lymphoma therapy (dpeaa)DE-He213 Alfaro Lizaso, J. verfasserin aut de la Cruz Merino, L. verfasserin aut Gumá i Padró, J. verfasserin aut Quero Blanco, C. verfasserin aut Gómez Codina, J. verfasserin aut Llanos Muñoz, M. verfasserin aut Martinez Banaclocha, N. verfasserin aut Rodriguez Abreu, D. verfasserin aut Provencio Pulla, M. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 17(2015), 12 vom: 26. Okt., Seite 1005-1013 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:17 year:2015 number:12 day:26 month:10 pages:1005-1013 https://dx.doi.org/10.1007/s12094-015-1429-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 17 2015 12 26 10 1005-1013
allfieldsGer	10.1007/s12094-015-1429-1 doi (DE-627)SPR024262714 (SPR)s12094-015-1429-1-e DE-627 ger DE-627 rakwb eng 610 ASE Rueda Domínguez, A. verfasserin aut SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. Oncohematology malignancies (dpeaa)DE-He213 Hodgkin lymphoma (dpeaa)DE-He213 Hodgkin lymphoma therapy (dpeaa)DE-He213 Alfaro Lizaso, J. verfasserin aut de la Cruz Merino, L. verfasserin aut Gumá i Padró, J. verfasserin aut Quero Blanco, C. verfasserin aut Gómez Codina, J. verfasserin aut Llanos Muñoz, M. verfasserin aut Martinez Banaclocha, N. verfasserin aut Rodriguez Abreu, D. verfasserin aut Provencio Pulla, M. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 17(2015), 12 vom: 26. Okt., Seite 1005-1013 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:17 year:2015 number:12 day:26 month:10 pages:1005-1013 https://dx.doi.org/10.1007/s12094-015-1429-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 17 2015 12 26 10 1005-1013
allfieldsSound	10.1007/s12094-015-1429-1 doi (DE-627)SPR024262714 (SPR)s12094-015-1429-1-e DE-627 ger DE-627 rakwb eng 610 ASE Rueda Domínguez, A. verfasserin aut SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. Oncohematology malignancies (dpeaa)DE-He213 Hodgkin lymphoma (dpeaa)DE-He213 Hodgkin lymphoma therapy (dpeaa)DE-He213 Alfaro Lizaso, J. verfasserin aut de la Cruz Merino, L. verfasserin aut Gumá i Padró, J. verfasserin aut Quero Blanco, C. verfasserin aut Gómez Codina, J. verfasserin aut Llanos Muñoz, M. verfasserin aut Martinez Banaclocha, N. verfasserin aut Rodriguez Abreu, D. verfasserin aut Provencio Pulla, M. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 17(2015), 12 vom: 26. Okt., Seite 1005-1013 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:17 year:2015 number:12 day:26 month:10 pages:1005-1013 https://dx.doi.org/10.1007/s12094-015-1429-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 17 2015 12 26 10 1005-1013
language	English
source	Enthalten in Revista de oncología 17(2015), 12 vom: 26. Okt., Seite 1005-1013 volume:17 year:2015 number:12 day:26 month:10 pages:1005-1013
sourceStr	Enthalten in Revista de oncología 17(2015), 12 vom: 26. Okt., Seite 1005-1013 volume:17 year:2015 number:12 day:26 month:10 pages:1005-1013
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Oncohematology malignancies Hodgkin lymphoma Hodgkin lymphoma therapy
dewey-raw	610
isfreeaccess_bool	true
container_title	Revista de oncología
authorswithroles_txt_mv	Rueda Domínguez, A. @@aut@@ Alfaro Lizaso, J. @@aut@@ de la Cruz Merino, L. @@aut@@ Gumá i Padró, J. @@aut@@ Quero Blanco, C. @@aut@@ Gómez Codina, J. @@aut@@ Llanos Muñoz, M. @@aut@@ Martinez Banaclocha, N. @@aut@@ Rodriguez Abreu, D. @@aut@@ Provencio Pulla, M. @@aut@@
publishDateDaySort_date	2015-10-26T00:00:00Z
hierarchy_top_id	385985452
dewey-sort	3610
id	SPR024262714
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR024262714</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519164623.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-015-1429-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR024262714</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-015-1429-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rueda Domínguez, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncohematology malignancies</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hodgkin lymphoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hodgkin lymphoma therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alfaro Lizaso, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de la Cruz Merino, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gumá i Padró, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quero Blanco, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gómez Codina, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Llanos Muñoz, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martinez Banaclocha, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rodriguez Abreu, D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Provencio Pulla, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">17(2015), 12 vom: 26. Okt., Seite 1005-1013</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:12</subfield><subfield code="g">day:26</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:1005-1013</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-015-1429-1</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2015</subfield><subfield code="e">12</subfield><subfield code="b">26</subfield><subfield code="c">10</subfield><subfield code="h">1005-1013</subfield></datafield></record></collection>
author	Rueda Domínguez, A.
spellingShingle	Rueda Domínguez, A. ddc 610 misc Oncohematology malignancies misc Hodgkin lymphoma misc Hodgkin lymphoma therapy SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma
authorStr	Rueda Domínguez, A.
ppnlink_with_tag_str_mv	@@773@@(DE-627)385985452
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1578-195X
topic_title	610 ASE SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma Oncohematology malignancies (dpeaa)DE-He213 Hodgkin lymphoma (dpeaa)DE-He213 Hodgkin lymphoma therapy (dpeaa)DE-He213
topic	ddc 610 misc Oncohematology malignancies misc Hodgkin lymphoma misc Hodgkin lymphoma therapy
topic_unstemmed	ddc 610 misc Oncohematology malignancies misc Hodgkin lymphoma misc Hodgkin lymphoma therapy
topic_browse	ddc 610 misc Oncohematology malignancies misc Hodgkin lymphoma misc Hodgkin lymphoma therapy
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Revista de oncología
hierarchy_parent_id	385985452
dewey-tens	610 - Medicine & health
hierarchy_top_title	Revista de oncología
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)385985452 (DE-600)2143451-7
title	SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma
ctrlnum	(DE-627)SPR024262714 (SPR)s12094-015-1429-1-e
title_full	SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma
author_sort	Rueda Domínguez, A.
journal	Revista de oncología
journalStr	Revista de oncología
lang_code	eng
isOA_bool	true
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2015
contenttype_str_mv	txt
container_start_page	1005
author_browse	Rueda Domínguez, A. Alfaro Lizaso, J. de la Cruz Merino, L. Gumá i Padró, J. Quero Blanco, C. Gómez Codina, J. Llanos Muñoz, M. Martinez Banaclocha, N. Rodriguez Abreu, D. Provencio Pulla, M.
container_volume	17
class	610 ASE
format_se	Elektronische Aufsätze
author-letter	Rueda Domínguez, A.
doi_str_mv	10.1007/s12094-015-1429-1
dewey-full	610
author2-role	verfasserin
title_sort	seom clinical guidelines for the treatment of hodgkin’s lymphoma
title_auth	SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma
abstract	Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.
abstractGer	Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.
abstract_unstemmed	Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702
container_issue	12
title_short	SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma
url	https://dx.doi.org/10.1007/s12094-015-1429-1
remote_bool	true
author2	Alfaro Lizaso, J. de la Cruz Merino, L. Gumá i Padró, J. Quero Blanco, C. Gómez Codina, J. Llanos Muñoz, M. Martinez Banaclocha, N. Rodriguez Abreu, D. Provencio Pulla, M.
author2Str	Alfaro Lizaso, J. de la Cruz Merino, L. Gumá i Padró, J. Quero Blanco, C. Gómez Codina, J. Llanos Muñoz, M. Martinez Banaclocha, N. Rodriguez Abreu, D. Provencio Pulla, M.
ppnlink	385985452
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1007/s12094-015-1429-1
up_date	2024-07-04T00:12:50.865Z
_version_	1803605215405932544
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR024262714</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519164623.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-015-1429-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR024262714</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-015-1429-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rueda Domínguez, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncohematology malignancies</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hodgkin lymphoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hodgkin lymphoma therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alfaro Lizaso, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de la Cruz Merino, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gumá i Padró, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quero Blanco, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gómez Codina, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Llanos Muñoz, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martinez Banaclocha, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rodriguez Abreu, D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Provencio Pulla, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">17(2015), 12 vom: 26. Okt., Seite 1005-1013</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:12</subfield><subfield code="g">day:26</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:1005-1013</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-015-1429-1</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2015</subfield><subfield code="e">12</subfield><subfield code="b">26</subfield><subfield code="c">10</subfield><subfield code="h">1005-1013</subfield></datafield></record></collection>
score	7.4006386

Nicht das Richtige dabei?

Schreiben Sie uns!

SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?